← Eichor
Study identifier: NCT06679920 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment

Condition: Bladder Cancer  ·  Sponsor: Amsterdam UMC

PhaseNA
Planned participants15
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to see if a new designed optical coherence tomography catheter can be used in bladder cancer in patients undergoing a transurethral resection of a bladder tumour. The main question it aims to answer is: \- Is the optical coherence tomography catheter feasible in capturing images of bladder tumours and normal bladder wall during a transurethral resection of a bladder tumour? Participants will undergo measurements with a new optical coherence tomography device during the transurethral resection of their bladder tumour(s).

This description comes directly from the study's public registry record.

Talk to the study team

Marinka Remmelink, MD  ·  +310204441376  ·  m.j.remmelink@amsterdamumc.nl

Jorg R Oddens, MD, PhD  ·  j.r.oddens@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (2)

Amsterdam University Medical CenterAmsterdam, North Holland, NetherlandsNot Yet Recruiting
Amsterdam University Medical CenterAmsterdam, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06679920